Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer Academic Article Article uri icon


MeSH Major

  • Algorithms
  • Fetal Growth Retardation
  • Image Enhancement
  • Image Interpretation, Computer-Assisted
  • Infant, Small for Gestational Age
  • Ultrasonography, Prenatal


  • We treated 28 patients who had no prior chemotherapy for stage IV breast cancer and 51 patients with extensive prior exposure to other chemotherapeutic agents with a 24-hour infusion of Taxol (paclitaxel) as a single agent. Prophylactic recombinant human granulocyte colony-stimulating factor was administered routinely to ameliorate the anticipated dose-limiting toxicity of neutropenia. Nonhematologic toxicity was mild to moderate in most cases. Taxol was more active in patients with chemotherapy-naive stage IV disease, but activity was also observed in extensively treated patients as well. There is a strong clinical suggestion of at least partial noncross-resistance with doxorubicin. Taxol is a very promising agent for the treatment of metastatic breast cancer; its optimal application in this disease will be the subject of future trials.

publication date

  • January 1994



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1159/000227414

PubMed ID

  • 7526308

Additional Document Info

start page

  • 33

end page

  • 9


  • 51